News
03-03-2011, 06:21 AM
The committee's decision stands in stark contrast to the recent verdict by the U.S. Food and Drug Administration, which is wary of Avastin's benefits for breast-cancer patients.
More... (http://www.news-medical.net/news/20110303/EUs-Avastin-policy-A-stark-contrast-to-the-FDAs-recent-decision.aspx)
More... (http://www.news-medical.net/news/20110303/EUs-Avastin-policy-A-stark-contrast-to-the-FDAs-recent-decision.aspx)